Journal Watch · Frontiers in Immunology · 2026
CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma.
Furthermore, CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells via the BTLA-TNFRSF14 pathway.<h4>Conclusions</h4>This study highlights the critical role of CD244 in NK cell dysfunction and DLBCL progression, providing a promising target for optimizing immunotherapy.
TL;DR
Furthermore, CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells via the BTLA-TNFRSF14 pathway.<h4>Conclusions</h4>This study highlights the critical role of CD244 in NK cell dysfunction and DLBCL progression, providing a promising target for optimizing immunotherapy.
Key findings
- EAT2 was identified as CD244's predominant intracellular adaptor, suggesting that CD244-associated inhibitory signaling may contribute to metabolic dysregulation and immune dysfunction in NK cells.
- Elevated CD244 expression correlated with an immunosuppressive TME, worse clinicopathological features, poorer outcomes, and increased potential responsiveness to ICB.
- Furthermore, CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells via the BTLA-TNFRSF14 pathway.<h4>Conclusions</h4>This study highlights the critical role of CD244 in NK cell dysfunction and DLBCL progression, providing a promising target for optimizing immunotherapy.
What they did
The clinical and biological implications of CD244 expression, including associations with clinicopathological characteristics, TME composition, prognosis, and response to immune checkpoint blockade (ICB) therapy, were investigated by integrating single-cell and bulk RNA sequencing, immunohistochemistry, and reverse transcription-quantitative polymerase chain reaction. Intercellular communication networks, key transcription factors, and somatic mutations were further evaluated to uncover regulatory mechanisms.<h4>Results</h4>NK cells were the primary CD244-expressing population in DLBCL, co-overexpressing PDCD1, CTLA4, LAG3, TIGIT, PTGER4, and CD160.
Full abstract (original)
Background: <h4>Background</h4>CD244, expressed in the tumor microenvironment (TME), is associated with impaired function of natural killer (NK) and T cells; however, its role in diffuse large B-cell lymphoma (DLBCL) remains poorly understood. This study aimed to elucidate the immunological significance and regulatory mechanisms of CD244 in DLBCL.<h4>Methods</h4>Using single-cell and bulk RNA sequencing, we analyzed CD244 expression patterns, its major intracellular adaptor molecules, and correlations with immune checkpoints, metabolic alterations, and immune activity.
What they did: The clinical and biological implications of CD244 expression, including associations with clinicopathological characteristics, TME composition, prognosis, and response to immune checkpoint blockade (ICB) therapy, were investigated by integrating single-cell and bulk RNA sequencing, immunohistochemistry, and reverse transcription-quantitative polymerase chain reaction. Intercellular communication networks, key transcription factors, and somatic mutations were further evaluated to uncover regulatory mechanisms.<h4>Results</h4>NK cells were the primary CD244-expressing population in DLBCL, co-overexpressing PDCD1, CTLA4, LAG3, TIGIT, PTGER4, and CD160.
Results & conclusions: EAT2 was identified as CD244's predominant intracellular adaptor, suggesting that CD244-associated inhibitory signaling may contribute to metabolic dysregulation and immune dysfunction in NK cells. Elevated CD244 expression correlated with an immunosuppressive TME, worse clinicopathological features, poorer outcomes, and increased potential responsiveness to ICB. Furthermore, CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells via the BTLA-TNFRSF14 pathway.<h4>Conclusions</h4>This study highlights the critical role of CD244 in NK cell dysfunction and DLBCL progression, providing a promising target for optimizing immunotherapy.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1855521 · PubMed 42483169.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Furthermore, CD244 expression may be regulated by STAT3 activation in NK cells and ASXL3 mutations in tumor cells via the BTLA-TNFRSF14 pathway.<h4>Conclusions</h4>This study highlights the critical role of CD244 in NK cell dysfunction and DLBCL progression, providing a promising target for optimizing immunotherapy.
What type of study is this?
It is a genomics / omics study, published in Frontiers in Immunology in 2026. The clinical and biological implications of CD244 expression, including associations with clinicopathological characteristics, TME composition, prognosis, and response to immune checkpoint blockade (ICB) therapy, were investigated by integrating single-cell and bulk RNA sequencing, immunohistochemistry, and reverse transcription-quantitative polymerase chain reaction.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1855521. PubMed ID: 42483169. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd244-overexpression-indicates-nk-cell-dysfunction-and-tumor-progression-855521/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides